Presence of a High Amount of Stroma and Downregulation of SMAD4 Predict for Worse Survival for Stage I–II Colon Cancer Patients

Presence of a High Amount of Stroma and Downregulation of SMAD4 Predict for Worse Survival for Stage I–II Colon Cancer Patients

Background: For stage I–II colon cancer a significant number (5–25%) of patients has recurrent disease within 5 years. There is need to identify these high-risk patients as they might benefit from additional treatment.

Saved in:
Bibliographic Details
Main Authors: Wilma E. Mesker, Gerrit-Jan Liefers, Jan M. C. Junggeburt, Gabi W. van Pelt, Paola Alberici, Peter J. K. Kuppen, Noel F. Miranda, Karin A. M. van Leeuwen, Hans Morreau, Karoly Szuhai, Rob A. E. M. Tollenaar, Hans J. Tanke
Format: Article
Language:English
Published: Wiley 2009-01-01
Series:Cellular Oncology
Online Access:http://dx.doi.org/10.3233/CLO-2009-0478
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items